Previous close | 0.9500 |
Open | 0.9600 |
Bid | 0.9473 x 200 |
Ask | 0.9844 x 200 |
Day's range | 0.9575 - 0.9999 |
52-week range | 0.7310 - 2.2900 |
Volume | |
Avg. volume | 363,669 |
Market cap | 57.691M |
Beta (5Y monthly) | 1.83 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
SAN MATEO, Calif. and CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that it will present a study update of the oral CDK9 inhibitor KB-0742 in relapsed or refractory transcriptionally addicted advanced solid tumors from the ongoing Phase 1/2 trial, KB-0742-1001 (NCT04718675), at the American Society of Clinical Oncology (ASCO) Annual Meeting, being held from May 31 –
Phase 1/2 study of KB-0742 is on track to clear 80mg four-days-on, three-days-off schedule in the third quarter of 2024; topline data from expansion cohort at this schedule expected in the first half of 2025 IND-enabling studies for KB-9558 expected to complete in 2024 with first-in-human study anticipated to commence in the first half of 2025 $175.0 million in cash, cash equivalents and investments as of December 31, 2023, providing expected cash runway into the second half of 2026 SAN MATEO, C
Company to assess KB-0742 at planned new dose schedule in ongoing phase 1/2 study; topline data from expansion cohort at new dose schedule expected in the first half of 2025 IND-enabling studies for KB-9558 expected to complete in 2024 with first-in-human study anticipated to commence in 2025 Restructuring plan extends anticipated cash runway into the second half of 2026 Company to continue to focus discovery efforts on maturing projects and Genentech collaboration activities SAN MATEO, Calif.,